文献速递慢性肾脏病

不确定潜能克隆性造血与普通人群肾功能下降

Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population.
PubMed 文献 · Am J Kidney Dis · 2022-10-11

基于TOPMed联盟3个社区队列12,004人的队列研究显示,中位基线eGFR为84mL/min/1.73m2,中位随访8年期间,CHIP与30% eGFR下降风险升高17%(95% CI 1%-36%,P=0.04)相关,且该关联在基线eGFR高于或低于60mL/min/1.73m2、年龄高于或低于60岁、有无糖尿病者之间无差异。

要点

  • CHIP患病率随年龄增加:50-60岁为6.6%,60-70岁为9.0%,>70岁为12.2%。
  • 中位随访8年,CHIP携带者30% eGFR下降发生率为2.1例/100人年,非携带者为1.7例/100人年。
  • CHIP与30% eGFR下降风险升高17%(95% CI 1%-36%,P=0.04)相关。

核心结论

  • 在3个无已知肾脏病的普通人群队列中,CHIP与eGFR下降存在关联。
  • 需要进一步研究以探讨这一新情况及其在明显肾脏病患者中的潜在影响。

研究设计与样本

  • 队列研究,纳入TOPMed联盟3个社区队列的12,004人。
  • 暴露为从外周血DNA全基因组测序获得的CHIP状态。
  • 结局为随访期间30% eGFR下降风险及每年eGFR下降百分比。
  • 采用Cox比例风险模型分析30% eGFR下降终点,采用广义估计方程分析eGFR年化相对变化,并使用固定效应Meta分析合并研究特异性估计值。

主要发现

  • 中位基线eGFR为84mL/min/1.73m2。
  • CHIP患病率在50-60岁、60-70岁和>70岁人群中分别为6.6%、9.0%和12.2%。
  • 中位随访8年期间,1,002名CHIP携带者中发生205例30% eGFR下降事件(2.1例/100人年),无CHIP者中发生2,041例事件(1.7例/100人年)。
  • Meta分析显示,CHIP与30% eGFR下降风险升高17%(95% CI 1%-36%,P=0.04)相关。
  • 基线eGFR高于或低于60mL/min/1.73m2、年龄高于或低于60岁、有无糖尿病者之间未观察到差异。

局限性

  • 中重度肾脏病参与者数量少。
  • CHIP驱动变异集合有限。
  • 需要进一步研究以探讨这一新情况及其在明显肾脏病患者中的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Clonal hematopoiesis of indeterminate potential (CHIP), defined by the age-related ontogenesis of expanded leukemogenic variants indicative of a genetically distinct clonal leukocyte population, is associated with risk of hematologic malignancy and cardiovascular disease. In experimental models, recapitulation of CHIP promotes kidney interstitial fibrosis with direct tissue infiltration of donor macrophages. We tested the hypothesis that CHIP is associated with kidney function decline in the general population. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: 12,004 individuals from 3 community-based cohorts in the TOPMed Consortium. EXPOSURE: CHIP status from whole-genome sequences obtained from DNA extracted from peripheral blood. OUTCOME: Risk of 30% decline in estimated glomerular filtration rate (eGFR) and percent eGFR decline per year during the follow-up period. ANALYTICAL APPROACH: Cox proportional hazards models for 30% eGFR decline end point and generalized estimating equations for annualized relative change in eGFR with meta-analysis. Study-specific estimates were combined using fixed-effect meta-analysis. RESULTS: The median baseline eGFR was 84mL/min/1.73m2. The prevalence of CHIP was 6.6%, 9.0%, and 12.2% in persons aged 50-60, 60-70, and>70 years, respectively. Over a median follow-up period of 8 years, for the 30% eGFR outcome 205 events occurred among 1,002 CHIP carriers (2.1 events per 100 person-years) and 2,041 events in persons without CHIP (1.7 events per 100 person-years). In meta-analysis, CHIP was associated with greater risk of a 30% eGFR decline (17% [95% CI, 1%-36%] higher; P=0.04). Differences were not observed between those with baseline eGFR above or below 60mL/min/1.73m2, of age above or below 60 years, or with or without diabetes. LIMITATIONS: Small number of participants with moderate-to-advanced kidney disease and restricted set of CHIP driver variants. CONCLUSIONS: We report an association between CHIP and eGFR decline in 3 general population cohorts without known kidney disease. Further studies are needed to investigate this novel condition and its potential impact among individuals with overt kidney disease.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Kestenbaum B, Bick AG, Vlasschaert C, et al. Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population. Am J Kidney Dis. 2022. PMID: 36241009. doi:10.1053/j.ajkd.2022.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。